LENSAR (NASDAQ:LNSR – Get Free Report) and Quipt Home Medical (NASDAQ:QIPT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Valuation & Earnings
This table compares LENSAR and Quipt Home Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENSAR | $48.87 million | 1.83 | -$14.38 million | ($1.46) | -5.27 |
| Quipt Home Medical | $245.92 million | 0.44 | -$2.78 million | ($0.15) | -16.60 |
Quipt Home Medical has higher revenue and earnings than LENSAR. Quipt Home Medical is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
Profitability
This table compares LENSAR and Quipt Home Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LENSAR | -34.03% | -49.02% | -21.12% |
| Quipt Home Medical | -1.95% | -4.51% | -2.01% |
Analyst Ratings
This is a breakdown of recent ratings and target prices for LENSAR and Quipt Home Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENSAR | 0 | 0 | 1 | 0 | 3.00 |
| Quipt Home Medical | 1 | 0 | 3 | 2 | 3.00 |
LENSAR presently has a consensus price target of $8.00, suggesting a potential upside of 3.90%. Quipt Home Medical has a consensus price target of $6.25, suggesting a potential upside of 151.00%. Given Quipt Home Medical’s higher probable upside, analysts plainly believe Quipt Home Medical is more favorable than LENSAR.
Volatility & Risk
LENSAR has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Quipt Home Medical has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
Summary
Quipt Home Medical beats LENSAR on 10 of the 14 factors compared between the two stocks.
About LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
About Quipt Home Medical
Quipt Home Medical Corp., through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States. The company offers nebulizers, oxygen concentrators, and CPAP and BiPAP units; traditional and non-traditional durable medical respiratory equipment and services; non-invasive ventilation equipment, supplies, and services; and engages in the rental of medical equipment. It offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep apnea, reduced mobility, and other chronic health conditions. The company was formerly known as Protech Home Medical Corp. and changed its name to Quipt Home Medical Corp. in May 2021. Quipt Home Medical Corp. is headquartered in Wilder, Kentucky.
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.
